Pulmonary Arterial Hypertension Complicating Connective Tissue Diseases

 

 Buy Article Permissions and Reprints

ABSTRACT

Pulmonary arterial hypertension (PAH) may complicate diverse connective tissue diseases (CTDs) such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and mixed CTD (MCTD) and is an important cause of morbidity and mortality in this context. From a histological standpoint, the pulmonary vascular lesions in PAH complicating CTD are similar to those observed in idiopathic PAH (IPAH). However, prognosis and responsiveness to therapy are distinctly worse in PAH associated with CTD. PAH is most common in SSc (affecting up to 20% of patients with SSc), and most of the data regarding incidence, clinical features, and therapy of CTD-associated PAH are derived from patients with SSc (scleroderma). Although PAH may involve other CTDs, data are more limited (primarily small, uncontrolled series and case reports). Treatment strategies for PAH associated with CTD are similar to but are distinctly less effective than those for IPAH. Lung transplantation may be offered for a subset of patients with CTD-associated PAH, but results are less favorable than for IPAH due to comorbidities and specific complications associated with CTD (e.g., esophageal involvement, aspiration with SSc).

REFERENCES

• 1 D'Alonzo G E, Barst R J, Ayres S M et al.. Survival in patients with primary pulmonary hypertension: results from a national prospective registry.  Ann Intern Med. 1991;  115 343-349
  PubMedGoogle Scholar
• 2 Kawut S M, Taichman D B, Archer-Chicko C L, Palevsky H I, Kimmel S E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis.  Chest. 2003;  123 344-350
  CrossrefPubMedGoogle Scholar
• 3 Fisher M R, Mathai S C, Champion H C et al.. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.  Arthritis Rheum. 2006;  54 3043-3050
  CrossrefPubMedGoogle Scholar
• 4 Jimenez S A, Derk C T. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis.  Ann Intern Med. 2004;  140 37-50
  PubMedGoogle Scholar
• 5 Tan F K. Systemic sclerosis: the susceptible host (genetics and environment).  Rheum Dis Clin North Am. 2003;  29 211-237
  CrossrefPubMedGoogle Scholar
• 6 LeRoy E C, Black C, Fleischmajer R et al.. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.  J Rheumatol. 1988;  15 202-205
  PubMedGoogle Scholar
• 7 Mayes M D, Lacey Jr J V, Beebe-Dimmer J et al.. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.  Arthritis Rheum. 2003;  48 2246-2255
  CrossrefPubMedGoogle Scholar
• 8 Mayes M D. Scleroderma epidemiology.  Rheum Dis Clin North Am. 2003;  29 239-254
  CrossrefPubMedGoogle Scholar
• 9 Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo.  Arch Dermatol Res. 1991;  283 366-371
  CrossrefPubMedGoogle Scholar
• 10 Allcock R J, Forrest I, Corris P A, Crook P R, Griffiths I D. A study of the prevalence of systemic sclerosis in northeast England.  Rheumatology (Oxford). 2004;  43 596-602
  CrossrefPubMedGoogle Scholar
• 11 Battle R W, Davitt M A, Cooper S M et al.. Prevalence of pulmonary hypertension in limited and diffuse scleroderma.  Chest. 1996;  110 1515-1519
  CrossrefPubMedGoogle Scholar
• 12 Stupi A M, Steen V D, Owens G R, Barnes E L, Rodnan G P, Medsger Jr T A. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.  Arthritis Rheum. 1986;  29 515-524
  CrossrefPubMedGoogle Scholar
• 13 Sacks D G, Okano Y, Steen V D, Curtiss E, Shapiro L S, Medsger Jr T A. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody.  J Rheumatol. 1996;  23 639-642
  PubMedGoogle Scholar
• 14 MacGregor A J, Canavan R, Knight C et al.. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival.  Rheumatology (Oxford). 2001;  40 453-459
  CrossrefPubMedGoogle Scholar
• 15 Hachulla E, Gressin V, Guillevin L et al.. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.  Arthritis Rheum. 2005;  52 3792-3800
  CrossrefPubMedGoogle Scholar
• 16 Mukerjee D, St George D, Coleiro B et al.. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.  Ann Rheum Dis. 2003;  62 1088-1093
  CrossrefPubMedGoogle Scholar
• 17 Peacock A J, Murphy N F, McMurray J J, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension.  Eur Respir J. 2007;  30 104-109
  CrossrefPubMedGoogle Scholar
• 18 Condliffe R, Kiely D G, Peacock A J et al.. Connective tissue disease–associated pulmonary arterial hypertension in the modern treatment era.  Am J Respir Crit Care Med. 2009;  179 151-157
  CrossrefPubMedGoogle Scholar
• 19 LeRoy E C. Systemic sclerosis: a vascular perspective.  Rheum Dis Clin North Am. 1996;  22 675-694
  CrossrefPubMedGoogle Scholar
• 20 Sgonc R, Gruschwitz M S, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95.  Arthritis Rheum. 2000;  43 2550-2562
  CrossrefPubMedGoogle Scholar
• 21 Cerinic M M, Valentini G, Sorano G G et al.. Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis.  Semin Arthritis Rheum. 2003;  32 285-295
  CrossrefPubMedGoogle Scholar
• 22 Altman R D, Medsger Jr T A, Bloch D A, Michel B A. Predictors of survival in systemic sclerosis (scleroderma).  Arthritis Rheum. 1991;  34 403-413
  CrossrefPubMedGoogle Scholar
• 23 Denton C P, Bickerstaff M C, Shiwen X et al.. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis.  Br J Rheumatol. 1995;  34 1048-1054
  CrossrefPubMedGoogle Scholar
• 24 Distler O, Del Rosso A, Giacomelli R et al.. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.  Arthritis Res. 2002;  4 R11
  CrossrefPubMedGoogle Scholar
• 25 Choi J J, Min D J, Cho M L et al.. Elevated vascular endothelial growth factor in systemic sclerosis.  J Rheumatol. 2003;  30 1529-1533
  PubMedGoogle Scholar
• 26 Hebbar M, Peyrat J P, Hornez L, Hatron P Y, Hachulla E, Devulder B. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis.  Arthritis Rheum. 2000;  43 889-893
  CrossrefPubMedGoogle Scholar
• 27 Okano Y, Steen V D, Medsger Jr T A. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis.  Arthritis Rheum. 1992;  35 95-100
  CrossrefPubMedGoogle Scholar
• 28 Negi V S, Tripathy N K, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension.  J Rheumatol. 1998;  25 462-466
  PubMedGoogle Scholar
• 29 Tamby M C, Chanseaud Y, Humbert M et al.. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension.  Thorax. 2005;  60 765-772
  CrossrefPubMedGoogle Scholar
• 30 Fritzler M J, Hart D A, Wilson D et al.. Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis.  J Rheumatol. 1995;  22 1688-1693
  PubMedGoogle Scholar
• 31 Grigolo B, Mazzetti I, Meliconi R et al.. Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.  Clin Exp Immunol. 2000;  121 539-543
  CrossrefPubMedGoogle Scholar
• 32 Nicolls M R, Taraseviciene-Stewart L, Rai P R, Badesch D B, Voelkel N F. Autoimmunity and pulmonary hypertension: a perspective.  Eur Respir J. 2005;  26 1110-1118
  CrossrefPubMedGoogle Scholar
• 33 Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Kinoshita M, Sumiya M. Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein.  Clin Exp Immunol. 1999;  116 174-180
  CrossrefPubMedGoogle Scholar
• 34 Chizzolini C, Raschi E, Rezzonico R et al.. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.  Arthritis Rheum. 2002;  46 1602-1613
  CrossrefPubMedGoogle Scholar
• 35 Tamby M C, Humbert M, Guilpain P et al.. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension.  Eur Respir J. 2006;  28 799-807
  CrossrefPubMedGoogle Scholar
• 36 Terrier B, Tamby M C, Camoin L et al.. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2008;  177 1128-1134
  CrossrefPubMedGoogle Scholar
• 37 Sanchez O, Sitbon O, Jaïs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension.  Chest. 2006;  130 182-189
  CrossrefPubMedGoogle Scholar
• 38 Jais X, Launay D, Yaici A et al.. Immunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases.  Arthritis Rheum. 2008;  58 521-531
  CrossrefPubMedGoogle Scholar
• 39 Austin E D, Loyd J E. Genetics and mediators in pulmonary arterial hypertension.  Clin Chest Med. 2007;  28 43-57 vii-viii
  CrossrefPubMedGoogle Scholar
• 40 Morse J H, Deng Z, Knowles J A. Genetic aspects of pulmonary arterial hypertension.  Ann Med. 2001;  33 596-603
  PubMedGoogle Scholar
• 41 Trembath R C, Thomson J R, Machado R D et al.. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.  N Engl J Med. 2001;  345 325-334
  CrossrefPubMedGoogle Scholar
• 42 Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations.  J Rheumatol. 2002;  29 2379-2381
  PubMedGoogle Scholar
• 43 Tew M B, Arnett F C, Reveille J D, Tan F K. Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases.  Arthritis Rheum. 2002;  46 2829-2830
  CrossrefPubMedGoogle Scholar
• 44 Wipff J, Kahan A, Hachulla E et al.. Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension.  Rheumatology (Oxford). 2007;  46 622-625
  PubMedGoogle Scholar
• 45 Schachna L, Wigley F M, Chang B, White B, Wise R A, Gelber A C. Age and risk of pulmonary arterial hypertension in scleroderma.  Chest. 2003;  124 2098-2104
  CrossrefPubMedGoogle Scholar
• 46 Chang B, Schachna L, White B, Wigley F M, Wise R A. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma.  J Rheumatol. 2006;  33 269-274
  PubMedGoogle Scholar
• 47 Steen V, Medsger Jr T A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.  Arthritis Rheum. 2003;  48 516-522
  CrossrefPubMedGoogle Scholar
• 48 Allanore Y, Borderie D, Avouac J et al.. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.  Arthritis Rheum. 2008;  58(1) 284-291
  CrossrefPubMedGoogle Scholar
• 49 Hsiao S H, Lee C Y, Chang S M, Lin S K, Liu C P. Right heart function in scleroderma: insights from myocardial Doppler tissue imaging.  J Am Soc Echocardiogr. 2006;  19 507-514
  PubMedGoogle Scholar
• 50 Lee C Y, Chang S M, Hsiao S H, Tseng J C, Lin S K, Liu C P. Right heart function and scleroderma: insights from tricuspid annular plane systolic excursion.  Echocardiography. 2007;  24 118-125
  CrossrefPubMedGoogle Scholar
• 51 Meune C, Avouac J, Wahbi K et al.. Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: a controlled study of 100 consecutive patients.  Arthritis Rheum. 2008;  58 1803-1809
  CrossrefPubMedGoogle Scholar
• 52 Overbeek M J, Lankhaar J W, Westerhof N et al.. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension.  Eur Respir J. 2008;  31 1160-1166
  CrossrefPubMedGoogle Scholar
• 53 Williams M H, Handler C E, Akram R et al.. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.  Eur Heart J. 2006;  27 1485-1494
  CrossrefPubMedGoogle Scholar
• 54 Forfia P R, Mathai S C, Fisher M R et al.. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2008;  177 1364-1369
  CrossrefPubMedGoogle Scholar
• 55 Williams M H, Das C, Handler C E et al.. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.  Heart. 2006;  92 926-932
  CrossrefPubMedGoogle Scholar
• 56 McLaughlin V V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.  Circulation. 2002;  106 1477-1482
  CrossrefPubMedGoogle Scholar
• 57 Steen V D, Medsger T A. Changes in causes of death in systemic sclerosis, 1972-2002.  Ann Rheum Dis. 2007;  66 940-944
  CrossrefPubMedGoogle Scholar
• 58 Bulkley B H, Ridolfi R L, Salyer W R, Hutchins G M. Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction.  Circulation. 1976;  53 483-490
  PubMedGoogle Scholar
• 59 Fernandes F, Ramires F J, Arteaga E, Ianni B M, Bonfá E S, Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study.  J Card Fail. 2003;  9 311-317
  CrossrefPubMedGoogle Scholar
• 60 Pope J. An update in pulmonary hypertension in systemic lupus erythematosus: do we need to know about it?.  Lupus. 2008;  17 274-277
  CrossrefPubMedGoogle Scholar
• 61 Haas C. Pulmonary hypertension associated with systemic lupus erythematosus [in French].  Bull Acad Natl Med. 2004;  188 985-997, discussion 997
  PubMedGoogle Scholar
• 62 Sullivan W D, Hurst D J, Harmon C E et al.. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease.  Medicine (Baltimore). 1984;  63 92-107
  CrossrefPubMedGoogle Scholar
• 63 Launay D, Hachulla E, Hatron P Y, Jais X, Simonneau G, Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature.  Medicine (Baltimore). 2007;  86 299-315
  CrossrefPubMedGoogle Scholar
• 64 Budhiraja R, Tuder R M, Hassoun P M. Endothelial dysfunction in pulmonary hypertension.  Circulation. 2004;  109 159-165
  CrossrefPubMedGoogle Scholar
• 65 Sitbon O, Humbert M, Jaïs X et al.. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.  Circulation. 2005;  111 3105-3111
  CrossrefPubMedGoogle Scholar
• 66 Humbert M, Sitbon O, Chaouat A et al.. Pulmonary arterial hypertension in France: results from a national registry.  Am J Respir Crit Care Med. 2006;  173 1023-1030
  CrossrefPubMedGoogle Scholar
• 67 Badesch D B, Tapson V F, McGoon M D et al.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial.  Ann Intern Med. 2000;  132 425-434
  PubMedGoogle Scholar
• 68 Simonneau G, Barst R J, Galie N Treprostinil Study Group et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.  Am J Respir Crit Care Med. 2002;  165 800-804
  CrossrefPubMedGoogle Scholar
• 69 Tapson V F, Gomberg-Maitland M, McLaughlin V V et al.. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.  Chest. 2006;  129 683-688
  CrossrefPubMedGoogle Scholar
• 70 Farber H W, Graven K K, Kokolski G, Korn J H. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.  J Rheumatol. 1999;  26 1195-1196
  PubMedGoogle Scholar
• 71 Palmer S M, Robinson L J, Wang A, Gossage J R, Bashore T, Tapson V F. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.  Chest. 1998;  113 237-240
  CrossrefPubMedGoogle Scholar
• 72 Channick R N, Simonneau G, Sitbon O et al.. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.  Lancet. 2001;  358 1119-1123
  CrossrefPubMedGoogle Scholar
• 73 Rubin L J, Badesch D B, Barst R J et al.. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
  CrossrefPubMedGoogle Scholar
• 74 Denton C P, Humbert M, Rubin L, Black C M. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.  Ann Rheum Dis. 2006;  65 1336-1340
  CrossrefPubMedGoogle Scholar
• 75 Girgis R E, Mathai S C, Krishnan J A, Wigley F M, Hassoun P M. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases.  J Heart Lung Transplant. 2005;  24 1626-1631
  CrossrefPubMedGoogle Scholar
• 76 Barst R J, Langleben D, Frost A STRIDE-1 Study Group et al. Sitaxsentan therapy for pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  169 441-447
  CrossrefPubMedGoogle Scholar
• 77 Girgis R E, Frost A E, Hill N S et al.. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.  Ann Rheum Dis. 2007;  66 1467-1472
  CrossrefPubMedGoogle Scholar
• 78 Galiè N, Olschewski H, Oudiz R J Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.  Circulation. 2008;  117 3010-3019
  CrossrefPubMedGoogle Scholar
• 79 Iannone F, Riccardi M T, Guiducci S et al.. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension.  Ann Rheum Dis. 2008;  67 1121-1126
  CrossrefPubMedGoogle Scholar
• 80 Jain M, Varga J. Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.  Expert Opin Pharmacother. 2006;  7 1487-1501
  CrossrefPubMedGoogle Scholar
• 81 Galiè N, Ghofrani H A, Torbicki A Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group et al. Sildenafil citrate therapy for pulmonary arterial hypertension.  N Engl J Med. 2005;  353 2148-2157
  CrossrefPubMedGoogle Scholar
• 82 Badesch D B, Hill N S, Burgess G SUPER Study Group et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.  J Rheumatol. 2007;  34 2417-2422
  PubMedGoogle Scholar
• 82a Galie N, Brundage B H, Ghofrani H A et al. Tadalafil therapy for pulmonary arterial hypertension.  Circulation. 2009;  119 2894-2903
  CrossrefPubMedGoogle Scholar
• 83 Simonneau G, Rubin L J, Galiè N PACES Study Group et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.  Ann Intern Med. 2008;  149 521-530
  CrossrefPubMedGoogle Scholar
• 84 Mathai S C, Girgis R E, Fisher M R et al.. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.  Eur Respir J. 2007;  29 469-475
  CrossrefPubMedGoogle Scholar
• 85 Hoeper M M, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.  Eur Respir J. 2004;  24 1007-1010
  CrossrefPubMedGoogle Scholar
• 86 Adnot S. Lessons learned from cancer may help in the treatment of pulmonary hypertension.  J Clin Invest. 2005;  115 1461-1463
  CrossrefPubMedGoogle Scholar
• 87 Schermuly R T, Dony E, Ghofrani H A et al.. Reversal of experimental pulmonary hypertension by PDGF inhibition.  J Clin Invest. 2005;  115 2811-2821
  CrossrefPubMedGoogle Scholar
• 88 Ghofrani H A, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension.  N Engl J Med. 2005;  353 1412-1413
  CrossrefPubMedGoogle Scholar
• 89 Patterson K C, Weissmann A, Ahmadi T, Farber H W. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension.  Ann Intern Med. 2006;  145 152-153
  CrossrefPubMedGoogle Scholar
• 90 Schachna L, Medsger Jr T A, Dauber J H et al.. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension.  Arthritis Rheum. 2006;  54 3954-3961
  CrossrefPubMedGoogle Scholar

Paul M HassounM.D. 

Johns Hopkins University, Division of Pulmonary and Critical Care Medicine

1830 East Monument St., Baltimore, MD 21205

Email: phassoun@jhmi.edu